Insulin Use and Poor COVID-19 Outcomes among Diabetes Patients: Association Not Necessarily Causation

Area of Science:

• Endocrinology
• Infectious Diseases
• Nephrology

Background:

• The relationship between insulin use and clinical outcomes in COVID-19 patients remains an area of significant clinical interest.
• Previous studies have explored glycemic control and its impact on COVID-19 severity.
• Hemoglobin A1c (HbA1c) is a common marker for long-term glucose control, but its accuracy can be affected by comorbidities.

Purpose of the Study:

• To address questions raised regarding the interpretation of our study on insulin use and COVID-19 outcomes.
• To clarify the feasibility of using HbA1c for glucose control assessment in patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD).
• To discuss the potential impact of metformin as a confounding variable and the implications for study interpretation.

Main Methods:

• Retrospective analysis of clinical data from COVID-19 patients.
• Utilized Hemoglobin A1c (HbA1c) as a primary measure of glucose control, acknowledging limitations in populations with CKD/ESRD.
• Considered potential confounders, including metformin use, within the context of statistical modeling limitations.

Main Results:

• The study identified an association between insulin use and clinical outcomes in COVID-19 patients.
• Acknowledged that HbA1c may be less accurate in patients with significant kidney disease (CKD/ESRD).
• Addressed concerns that findings might lead to the underutilization of essential insulin therapy.

Conclusions:

• Reiterated that the study's findings should not be misinterpreted to discourage necessary insulin use.
• Emphasized the need for careful surveillance of diabetic patients, particularly those with advanced disease, admitted with COVID-19.
• Highlighted the importance of appropriate diabetes management, including insulin therapy, while acknowledging observed associations.